Dupilumab, Skin Proteins and the Microbiome: What TREATKids Added Beyond EASI

Dr. Arsy Editorial Team · November 9, 2026

Real-world registries can examine outcomes beyond a clinician’s severity score. In TREATKids, researchers followed children and adolescents treated with dupilumab and paired routine clinical measures with epidermal proteins and skin-microbiome data in smaller subsets.^[4]

Clinical response at three months

The analysis included baseline data from 200 participants and follow-up data from 124. Mean baseline EASI was 16.5 and peak itch was 6.6. By month three, EASI-50, EASI-75 and EASI-90 responses were 87%, 60% and 30%, respectively.^[4]

Why subset biology needs caution

Tape-strip proteomics were assessed in a subset of 20 and microbiome testing in 48. These exploratory samples can reveal biological patterns but are much less precise than the clinical cohort. They cannot show that one protein or bacterial change explains every child’s improvement, nor can they establish that a commercial microbiome product would reproduce the effect.

Registry strengths and weaknesses

Routine-care data show how treatment performs outside a tightly controlled trial. Without random assignment, however, changes may reflect patient selection, concurrent care and incomplete follow-up. The 124 participants with follow-up may differ from those without it. Controlled pediatric dupilumab trials and current guidelines remain important context.^{[9][12][13][14]}

What matters to families

• Changes in itch, sleep and daily function
• Extent and severity of active lesions
• Eye symptoms, infections and other adverse events
• Adherence and practical treatment burden
• Whether goals are being met at planned follow-up

Biomarker research may eventually refine treatment selection, but current decisions still rely on the whole clinical picture, approved labeling and shared decision-making.

Product context

Dr. Arsy Moisturizer #003 is a cosmetic moisturizer for dry, sensitive and eczema-prone skin. It was not evaluated in the research above and is not a substitute for medical assessment or prescription care. Ask a pediatric clinician before using a specific product on a baby.

Related pediatric eczema research

• Does Childhood Eczema Lower Test Scores? A 3,641-Child Study Challenges Assumptions
• Pediatric Eczema Treatment Across Skin Colors: What the PEDISTAD Registry Observed
• Eczema and Child Growth: What a 1,329-Child PEDISTAD Analysis Can—and Cannot—Say
• Tapinarof Eczema Trials Across Skin Types: What the Subgroup Analysis Shows
• Related pediatric eczema guide
• Related pediatric eczema guide

Research and clinical references

1. Childhood atopic dermatitis and standardized testing: US birth cohort.
2. PEDISTAD systemic treatment outcomes by skin color.
3. PEDISTAD growth assessment in children under 12.
4. TREATKids clinical and molecular outcomes with dupilumab.
5. Tapinarof efficacy by race and Fitzpatrick skin type.
6. Atopic dermatitis and academic performance in Denmark and England.
7. Atopic dermatitis, sleep and cognition in US adults.
8. Eczema and educational attainment: systematic review.
9. Pediatric atopic dermatitis guideline.
10. AAP skin-directed management clinical report.
11. AAAAI/ACAAI atopic dermatitis guideline.
12. Dupilumab in children 6 months to younger than 6 years.
13. Dupilumab in children 6 to 11 years with severe atopic dermatitis.
14. Dupilumab in adolescents with atopic dermatitis.
15. Tapinarof ADORING phase 3 trials.
16. Long-term topical therapy in pediatric atopic dermatitis: ROAD study.
17. Atopic dermatitis and child height: systematic review.
18. Growth and nutritional status in children with atopic dermatitis.
19. Atopic dermatitis in skin of color: clinical considerations.
20. Racial and ethnic representation in atopic dermatitis trials.
21. Core outcome instruments for atopic eczema.
22. EASI validation across skin types.
23. Patient-Oriented Eczema Measure validation in children.
24. Atopic dermatitis quality-of-life burden in children and families.

Educational information only; not medical advice. Cited researchers and organizations do not endorse Dr. Arsy products.